JonesResearch downgraded Cassava Sciences to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences Issues Statement on Former Science Advisor
- Cassava Sciences says Dr. Wang had no involvement in Phase 3 simufilam trials
- Cassava continues selloff, shares now down 50% to $9.56
- Cassava sinks after grand jury indicts co-lead scientist on Alzheimer’s drug
- Cassava sinks 36% to $12.16 after DOJ charges co-developer of drug